The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen

For Immediate Release

Chicago, IL - December 23, 2016 - announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include CoLucid Pharmaceuticals, Inc.(NASDAQ: CLCD - Free Report) , Exelixis, Inc.(NASDAQ: EXEL - Free Report) , TESARO, Inc.(NASDAQ: TSRO - Free Report) and Achaogen, Inc.(NASDAQ: AKAO - Free Report) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday's Analyst Blog:

4 Biotech Stocks that More than Doubled in 2016

2016 has not been a great year for biotech stocks which were under intense pressure with issues like increasing political and media focus on high price tags for drugs and the changing competitive scenario weighing on the sector.

While there has always been dissatisfaction about the high prices of drugs, the issue picked pace last year in September when Hillary Clinton tweeted about "price gouging". Clinton's tweet was in response to news regarding a huge price hike (about 5,000%) taken by Turing Pharmaceuticals for a drug (Daraprim) that was approved by the FDA way back in 1953.

Needless to say, this caused a major furor considering growing concerns regarding the pricing and affordability of prescription drugs. Since then, drug stocks, especially biotechs, have found themselves under the scanner for price hikes and the high costs of important treatments.

Although the sector did react favorably to the surprise win of Donald Trump in the Presidential election in Nov 2016, investors were in for a rude shock with the President-elect recently saying that he does not like price increases. The NASDAQ Biotechnology index is down 19.1% year-to-date (YTD).

Medical - Biomedical and Genetics Industry 5YR % Return

However, despite the immense pressure on the sector, there were some biotech stocks that bucked the trend and more than doubled in 2016. Here is a look at 4 such stocks.

CoLucid Pharmaceuticals, Inc.(NASDAQ: CLCD - Free Report): Cambridge, MA-based CoLucid is working on the development a molecule for the acute treatment of migraine. The company's pipeline candidates utilize a new mechanism of action that could address the unmet needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those who are dissatisfied with existing therapies.

CoLucid's shares shot up in Sep 2016 with the company presenting positive data from a late-stage study on its lead pipeline candidate, lasmiditan. CoLucid's shares are up 331.9% YTD.

Exelixis, Inc.(NASDAQ: EXEL - Free Report): South San Francisco, CA-based Exelixis is focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. The company has had a phenomenal run in 2016 outperforming the Zacks categorized Medical/Biomedical Genetics industry by a huge margin. Exelixis' shares are up 189.3% YTD compared to the industry decline of 25.4%.

Exelixis' portfolio includes two products derived from cabozantinib -- Cabometyx tablets (treatment of advanced kidney cancer) and Cometriq capsules (treatment of certain forms of thyroid cancer). Another product, Cotellic, derived from cobimetinib, is marketed under a collaboration with Roche (for use in combination with Zelboraf to treat advanced melanoma).

Recently approved Cabometyx had a strong full quarter driven by METEOR data and commercial execution. The product already has a 19% share in the second line metastatic kidney cancer market and 35% of the third-line segment. A major catalyst for Exelixis would be approval for the first-line indication -- the company has already presented pretty impressive results in October for the first-line patient population and is looking to seek approval for this indication. The first-line patient population represents huge commercial potential.

Exelixis is evaluating Cabometyx in several studies for different types of cancer and has other candidates in its pipeline including CS-3150 (partnered with Daiichi Sankyo). The company has made significant progress towards its goal of becoming a profitable, fully integrated, commercial company. (Looking for the Best Stocks for 2017? Be among the first to see our Top Ten Stocks for 2017 portfolio here .)

TESARO, Inc.(NASDAQ: TSRO - Free Report): Waltham, MA-based TESARO is another cancer-focused company that saw its shares soaring in 2016 on impressive data. TESARO's shares shot up in Jun 2016 when the company presented impressive data on its PARP inhibitor, niraparib. YTD, TESARO's shares are up a whopping 161.5%. The company is currently seeking FDA approval for niraparib for a certain type of ovarian cancer -- the agency has granted the drug priority review with a response expected by Jun 30, 2017. Importantly, the FDA does not expect to hold an advisory committee meeting for the candidate. PARP inhibitors are currently being considered to be the next major class of therapeutics in oncology and represent immense commercial potential.

Achaogen, Inc.(NASDAQ: AKAO - Free Report): South San Francisco, CA-based Achaogen is another company that had a phenomenal run this year mainly due to positive data on its lead pipeline candidate. Shares are up 116.7% YTD with the stock receiving a major boost earlier this month when the company reported positive late-stage data on plazomicin. The candidate achieved the primary endpoint of non-inferiority (for the FDA) and superiority (for the European Medicines Agency - EMA) compared to meropenem in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). Results from another phase III study showed a lower rate of mortality or serious disease-related complications for plazomicin compared with colistin therapy in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE). Achaogen intends to seek FDA approval for the treatment in the second half of 2017 and EMA approval in 2018.

While Exelixis, TESARO and Achaogen are all Zacks Rank #3 (Hold) stocks, CoLucid is a Zacks Rank #2 (Buy) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Where Do Zacks' Investment Ideas Come From?

You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks free of charge. There is no better place to start your own stock search. Plus you can access the full list of must-avoid Zacks Rank #5 "Strong Sells" and other private research. See the stocks free >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on CLCD - FREE

Get the full Report on EXEL - FREE

Get the full Report on TSRO - FREE

Get the full Report on AKAO - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

COLUCID PHARMA (CLCD): Free Stock Analysis Report

EXELIXIS INC (EXEL): Free Stock Analysis Report

TESARO INC (TSRO): Free Stock Analysis Report

ACHOGEN INC (AKAO): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos